Source:http://linkedlifedata.com/resource/pubmed/id/11606119
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
2001-10-18
|
pubmed:abstractText |
A large number of aziridinyl quinones represented by series 1-9 were studied with respect to their DT-diaphorase substrate activity, DNA reductive alkylation, cytostatic/cytotoxic activity, and in vivo activity. As a result, generalizations have been made with respect with respect to the following: DT-diaphorase substrate design, DT-diaphorase-cytotoxicity quantitative structure-activity relationship (QSAR), and DNA reductive alkylating agent design. A saturating relationship exists between the substrate specificity for human recombinant DT-diaphorase and the cytotoxicity in the human H460 non-small-cell lung cancer cell line. The interpretation of this relationship is that reductive activation is no longer rate-limiting for substrates with high DT-diaphorase substrate specificities. High DT-diaphorase substrate specificity is not desirable in the indole and cylopent[b]indole systems because of the result is the loss of cancer selectivity along with increased toxicity. We conclude that aziridinyl quinones of this type should possess a substrate specificity (V(max)/K(M)) < 10 x 10(-4) s(-1) for DT-diaphorase in order not to be too toxic or nonselective. While some DNA alkylation was required for cytostatic and cytotoxic activity by series 1-9, too much alkylation results in loss of cancer selectivity as well as increased in vivo toxicity. Indeed, the most lethal compounds are the indole systems with a leaving group in the 3alpha-position (like the antitumor agent EO9). We conclude that relatively poor DNA alkylating agents (according to our assay) show the lowest toxicity with the highest antitumor activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aziridines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/NAD(P)H Dehydrogenase (Quinone)
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3545-62
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11606119-Alkylation,
pubmed-meshheading:11606119-Animals,
pubmed-meshheading:11606119-Antineoplastic Agents,
pubmed-meshheading:11606119-Aziridines,
pubmed-meshheading:11606119-Cattle,
pubmed-meshheading:11606119-DNA,
pubmed-meshheading:11606119-Humans,
pubmed-meshheading:11606119-Indoles,
pubmed-meshheading:11606119-Melanoma,
pubmed-meshheading:11606119-Mice,
pubmed-meshheading:11606119-Mice, Inbred C57BL,
pubmed-meshheading:11606119-Models, Molecular,
pubmed-meshheading:11606119-NAD(P)H Dehydrogenase (Quinone),
pubmed-meshheading:11606119-Quantitative Structure-Activity Relationship,
pubmed-meshheading:11606119-Tumor Cells, Cultured,
pubmed-meshheading:11606119-Xenograft Model Antitumor Assays
|
pubmed:year |
2001
|
pubmed:articleTitle |
Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
|
pubmed:affiliation |
Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA. ESkibo@ASU.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|